Vor Biopharma Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Vor Biopharma wird ein Gewinn- und Umsatzwachstum von 9.8% bzw. 78.3% pro Jahr prognostiziert, während der Gewinn pro Aktie um 22.4% pro Jahr wachsen soll.

Wichtige Informationen

9.8%

Wachstumsrate der Gewinne

22.4%

EPS-Wachstumsrate

Biotechs Gewinnwachstum	28.3%
Wachstumsrate der Einnahmen	78.3%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Good
Zuletzt aktualisiert	21 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Gewinn- und Umsatzwachstumsprognosen

NasdaqGS:VOR - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (USD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	8	-122	-84	-132	6
12/31/2025	1	-115	-115	-111	7
12/31/2024	N/A	-114	-116	-101	7
9/30/2024	N/A	-112	-100	-100	N/A
6/30/2024	N/A	-118	-105	-104	N/A
3/31/2024	N/A	-120	-108	-106	N/A
12/31/2023	N/A	-118	-101	-100	N/A
9/30/2023	N/A	-116	-96	-95	N/A
6/30/2023	N/A	-106	-87	-86	N/A
3/31/2023	N/A	-98	-93	-87	N/A
12/31/2022	N/A	-92	-94	-85	N/A
9/30/2022	N/A	-86	-94	-84	N/A
6/30/2022	N/A	-81	-92	-83	N/A
3/31/2022	N/A	-78	-79	-74	N/A
12/31/2021	N/A	-70	-73	-69	N/A
9/30/2021	N/A	-70	-69	-65	N/A
6/30/2021	N/A	-65	-61	-56	N/A
3/31/2021	N/A	-56	-53	-48	N/A
12/31/2020	N/A	-49	-40	-36	N/A
9/30/2020	N/A	-36	-31	-28	N/A
6/30/2020	N/A	-26	-25	-23	N/A
3/31/2020	N/A	-19	-17	-15	N/A
12/31/2019	N/A	-13	-11	-10	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: VOR wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Ertrag vs. Markt: VOR wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Hohe Wachstumserträge: VOR wird in den nächsten 3 Jahren voraussichtlich unrentabel bleiben.

Einnahmen vs. Markt: VORDie Einnahmen des Unternehmens (78.3% pro Jahr) werden voraussichtlich schneller wachsen als der Markt US (8.9% pro Jahr).

Hohe Wachstumseinnahmen: VORDie Einnahmen des Unternehmens (78.3% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von VOR in 3 Jahren voraussichtlich hoch sein wird

Vor Biopharma Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Price target decreased by 9.5% to US$11.94

Price target decreased by 7.2% to US$13.75

Price target decreased by 19% to US$14.82

Price target decreased to US$18.13

Price target decreased to US$21.88

Price target decreased to US$22.25

Recent updates

Price target decreased by 9.5% to US$11.94

Vor Biopharma Inc. Appoints Han Choi as Chief Financial Officer

Vor Biopharma (NASDAQ:VOR) Will Have To Spend Its Cash Wisely

New minor risk - Share price stability

Vor Bio Announces New Clinical Data from Its Ongoing Phase 1/2 VBP101 Study of Patients with Relapsed/Refractory AML Receiving trem-cel Followed by Mylotarg™

Vor Biopharma Receives Notice from Nasdaq Due to Non-Compliance with the Minimum Bid Price Requirement

Vor Biopharma Receives Notice from Nasdaq Due to Non-Compliance with the Minimum Bid Price Requirement

Vor Biopharma Inc.(NasdaqGS:VOR) dropped from Russell Small Cap Comp Value Index

Vor Biopharma Inc. Announces Management Appointments, Effective June 21, 2024

New minor risk - Market cap size

We're A Little Worried About Vor Biopharma's (NASDAQ:VOR) Cash Burn Rate

New minor risk - Financial position

Vor Bio Appoints Fouad Namouni to its Board of Directors

Vor Biopharma Inc., Annual General Meeting, May 23, 2024

New major risk - Financial position

Insufficient new directors

Vor Bio Doses First AML Patient with VCAR33 (ALLO)

Here's Why We're Watching Vor Biopharma's (NASDAQ:VOR) Cash Burn Situation

Vor Bio Presents Positive Data Update on Trem-cel at HSCT² Conference

Vor Bio Announces Multiple Clinical and Preclinical Presentations at ASH 2023 Highlight Vor Bio's Novel eHSC and CAR-T Platform

Will Vor Biopharma (NASDAQ:VOR) Spend Its Cash Wisely?

Price target decreased by 7.2% to US$13.75

New minor risk - Share price stability

Vor Biopharma Inc. Presents Updated Clinical Data from Patients Treated in VBP101

Vor Biopharma (NASDAQ:VOR) Is In A Good Position To Deliver On Growth Plans

Price target decreased by 19% to US$14.82

Is Vor Biopharma Inc. (NASDAQ:VOR) Trading At A 49% Discount?

Vor Biopharma Inc. Presents Clinical Data from VBP101

Vor Biopharma Inc. announced that it expects to receive $50 million in funding from RA Capital Management, L.P.

Vor Bio Announces First AML Patient Successfully Transplanted with VOR Bio's Investigational Trem-Cel (Vor33) and Tolerated Mylotarg(Tm)

Price target decreased to US$18.13

We Think Vor Biopharma (NASDAQ:VOR) Needs To Drive Business Growth Carefully

Vor Bio Appoints Eyal C. Attar, M.D. as Chief Medical Officer

Vor Bio appoints Eyal C. Attar as chief medical officer

Price target decreased to US$21.88

Price target decreased to US$22.25

Vor Biopharma Inc.(NasdaqGS:VOR) dropped from Russell 2500 Value Index

Is Vor Biopharma (NASDAQ:VOR) In A Good Position To Invest In Growth?

Vor Bio Successfully Demonstrates Multiplex Editing of Hematopoietic Stem Cells for Next-generation AML Treatment Presented at EHA

Price target decreased to US$24.25

Price target decreased to US$31.71

Vor Biopharma Inc. Announces Retirement of Christopher Slapak as Chief Medical Officer

High number of new directors

Vor Biopharma (NASDAQ:VOR) Is In A Good Position To Deliver On Growth Plans

Vor Biopharma Announces VOR33 Granted U.S. FDA Fast Track Designation for Acute Myeloid Leukemia

Vor Biopharma (NASDAQ:VOR) Is In A Good Position To Deliver On Growth Plans

Vor Biopharma Expects to Enroll First Patient in VOR33 Acute Myeloid Leukemia Phase 1/2A Clinical Trial in the Next Few Months

Vor Biopharma: Targeted Therapies For Transplants

We're Not Very Worried About Vor Biopharma's (NASDAQ:VOR) Cash Burn Rate

Vor Biopharma EPS misses by $0.03

Vor Biopharma Inc. has completed an IPO in the amount of $176.904306 million.

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken